Back to top

Optimistic Buy Rating for Perspective Therapeutics Driven by Promising Trial Results and Upcoming Catalysts

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Perspective Therapeutics. The associated price target is $10.00. Robert...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Perspective Therapeutics, Inc. (CATX)